Pharmaceutical Intermediates, Syntheses Material Intermediates
pharmaceutical raw material
white crystal powder
Medicine Grade, Tech Grade
Assay Test Method:
2 Years properly stored
Wuhan Hengheda Pharm
1 Kilogram/Kilograms per Week
Packaging & Delivery
Nootropics manufacturer high quality Fasoracetam CAS 110958-19-5 free sample
[Product Name]:fasoracetam powder
Fasoracetam, also known by its scientific name (5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one (which probably doesn’t roll of the tongue as well), is a powerful new nootropic that falls within the subclass of nootropics known as racetams. If you are familiar with nootropics, then you likely know that all racetams are derivatives of piracetam, the original nootropic. Many of these derivatives are more powerful and affect cognition in different ways than piracetam. Fasoracetam is a good example of a piracetam derivative that is stronger than piracetam.
Fasoracetam is the newest member of the racetam family of nootropics that is currently being developed as a potential non-stimulant ADHD treatment.
In 2015, fasoracetam was accepted by the US Food and Drug Administration’s Investigational New Drug program, which grants the developers permission to start human clinical trials and ship the drug across state lines.
Publicly-available human studies on fasoracetam are limited but positive, indicating it may effectively treat a specific form of childhood ADHD. Animal studies and anecdotal evidence from users suggest that it may also enhance memory, improve sleep, relieve anxiety and depression, and alleviate the symptoms of withdrawal from other drugs.
Fasoracetam was created in the 1990s by the Japanese pharmaceutical company Nippon Shinyaku as a possible treatment for vascular dementia. Development was halted after disappointing clinical trials, but in 2013 the clinical data on fasoracetam (sometimes referred to in research literature as NS-105 or NFC-1) was purchased by the US-based firm NeuroFix, a subsidiary of Aevi Genomic Medicine.
Clinical trials on fasoracetam started again in 2016, investigating the compound’s potential for treating Attention Deficit Hyperactivity Disorder (ADHD) in children who demonstrate a specific mutation of the glutamate receptor system. The trials suggested that fasoracetam has potential as a non-stimulant alternative to Adderall and other amphetamine derivatives for ADHD treatment.
A phase II proof-of-concept trial was planned for 2018 to investigate fasoracetam as an autism spectrum disorder (ASD) treatment.
Fasoracetam has not been officially approved for any use by the USFDA and is classified as a research chemical that is not intended for human use.